Alterations of E-cadherin and β-catenin in gastric cancer by Huiping, Chen et al.
BioMed  Central BMC Cancer
BMC Cancer  2001,  1 :16 Research article
Alterations of E-cadherin and β -catenin in gastric cancer
Chen Huiping1, Sigrun Kristjansdottir1, Jon G Jonasson1, 
Jonas Magnusson2, Valgardur Egilsson1 and Sigurdur Ingvarsson*3
Address: 1Department of Pathology, National University Hospital, 101 Reykjavík, Iceland, 2Department of Surgery, National University 
Hospital, 101 Reykjavík, Iceland and 3Institute for Experimental Pathology, Keldur, University of Iceland, 112 Reykjavík, Iceland
E-mail: Chen Huiping - chen@rsp.is; Sigrun Kristjansdottir - sigrunk@rsp.is; Jon G Jonasson - jongi@rsp.is; 
Jonas Magnusson - jonas@rsp.is; Valgardur Egilsson - valgarde@rsp.is; Sigurdur Ingvarsson* - siguring@hi.is
*Corresponding author
Abstract
Background: The E-cadherin-catenin complex plays a crucial role in epithelial cell-cell adhesion
and in the maintenance of tissue architecture. Perturbation in the expression or function of this
complex results in loss of intercellular adhesion, with possible consequent cell transformation and
tumour progression.
Methods: We studied the alterations of E-cadherin and β -catenin in a set of 50 primary gastric
tumours by using loss of heterozygosity (LOH) analysis, gene mutation screening, detection of
aberrant transcripts and immunohistochemistry (IHC).
Results: A high frequency (75%) of LOH was detected at 16q22.1 containing E-cadherin locus.
Three cases (6%) showed the identical missense mutation, A592T. This mutation is not likely to
contribute strongly to the carcinogenesis of gastric cancer, because a low frequency (1.6%) of this
mutation was also found in 187 normal individuals. We also detected a low frequency (0.36%, 0%)
of this mutation in 280 breast tumours and 444 other tumours, including colon and rectum, lung,
endometrium, ovary, testis, kidney, thyroid carcinomas and sarcomas, respectively. We also
analyzed the aberrant E-cadherin mRNAs in the gastric tumours and found that 7 tumours (18%)
had aberrant mRNAs in addition to the normal mRNA. These aberrant mRNAs may produce
abnormal E-cadherin molecules, resulting in weak cell-cell adhesion and invasive behaviour of
carcinoma cells. Reduced expression of E-cadherin and β -catenin was identified at the frequency of
42% and 28%, respectively. Specially, 11 tumours (22%) exhibited positive cytoplasmic staining for
β -catenin IHC. An association was found between reduced expression of E-cadherin and β -catenin.
Moreover, an association was detected between reduced expression of E-cadherin and diffuse
histotype.
Conclusion: Our results support the hypothesis that alterations of E-cadherin and β -catenin play
a role in the initiation and progression of gastric cancer.
Background
E-cadherin (120 kDa; chromosome 16q) is a classical
cadherin and forms the key functional component of ad-
herence junctions between epithelial cells [1]. It is bound
via a series of undercoat proteins, the catenins (α , β  and
γ ) to the actin cytoskeleton [1]. This linkage between
transmembranous cadherins and actin filaments of the
cytoskeleton is necessary to form strong cell-cell adhe-
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sion. An intact E-cadherin – catenin complex is required
for maintenance of normal intercellular adhesion. In
light of this, several groups have proposed that in carci-
nomas, E-cadherin functions as an invasion suppressor
molecule such that its loss permits or enhances the inva-
sion of adjacent normal tissues. Immunohistochemical
studies in human cancers, including gastric cancer, have
frequently shown that a proportion of invasive carcino-
mas and carcinomas in situ show aberrant levels of E-
cadherin and/or catenin expression in comparison to
their related normal tissue [2–4]. In general, E-cadherin
and catenin staining is strong in well-differentiated can-
cers that maintain their cell adhesiveness and are less in-
vasive, but is reduced in poorly-differentiated tumours
which have lost their cell-cell adhesion and show strong
invasive behaviour [2,3].
E-cadherin is involved in contact inhibition of cell
growth by inducing cell cycle arrest [5]. It has the ability
to inhibit cell proliferation by the upregulation of p27 in-
volved in the cell cycle regulation [5], although the mech-
anism by which E-cadherin regulates p27 is still unclear.
Therefore, E-cadherin, generally described as an inva-
sion suppressor [6], can act as a major growth/prolifera-
tion suppressor.
An important function of β -catenin in cell signalling, has
been elucidated [7]. In the absence of a mitotic signal
from outside the cell, β -catenin is sequestered in a com-
plex with the adenomatous polyposis coli (APC) gene
product, a serine threonine glycogen synthetase kinase
(GSK-3β ) and an adapter protein axin (or a homologue
conductin), enabling phosphorylation and degradation
of free β -catenin by the ubiquitin-proteasome system
[8]. When a mitotic signal is delivered by the Wnt path-
way, by association of the Wg/Wnt family of secreted
glycoproteins and their membrane receptor frizzled, it
leads to activation of the dishevelled (Dsh) protein,
which is recruited to the cell membrane. The activated
Dsh downregulates the protein complex, so that it can no
longer phosphorylate β -catenin, which is then not de-
graded. The release of β -catenin from the phosphoryla-
tion and degradation complex promotes β -catenin
stabilization and signalling. This results in an increase of
free cystolic β -catenin which translocates to the nucleus
and directly binds the transcription factors Lef and Tcf,
leading to the activation of gene expression. Therefore β -
catenin performs distinct functions in E-cadherin-medi-
ated cell-cell adhesion and in Wnt signalling [8].
Loss of the E-cadherin locus on the long arm of chromo-
some 16 (16q22) occurs in gastric (24%), hepatocellular
(50%), lobular breast (50–100%) and oesophageal
(66%) carcinomas [4,9–12]. There have been several re-
ports on E-cadherin gene mutations in human cancers
[13]. In poorly-differentiated tumours, such as lobular
breast cancer and diffuse-type gastric cancer, E-cadherin
mutations play an important role in tumour develop-
ment [14,15]. Several studies have reported germline
mutations in the E-cadherin gene in families with an in-
herited diffuse type of gastric cancer [16,17]. Only a mi-
nority of gastric cancers can be accounted for by E-
cadherin mutations. Frequent somatic mutations of β -
catenin gene have been found in small colorectal adeno-
mas and intestinal type gastric cancer [18,19]. Most of
the mutations involved the loss of serines or threonines
from the GSK-3β  phosphorylation region. Genetic alter-
ations in β -catenin abolishing cell-cell adhesiveness have
been observed in two gastric cancer cell lines, HSC39 and
40A; both derive from the same signet ring cell carcino-
ma of the stomach and show a diffuse growth pattern
[20,21]. This mutation results in a truncated β -catenin
that lacks the region for interaction with β -catenin.
Transfection of these cell lines with wild-type β -catenin
restores cellular adhesiveness [21].
Here, we performed E-cadherin and beta-catenin gene
mutation and expression analysis in a series of 50 prima-
ry gastric tumours in order to understand better the in-
volvement of the alterations of E-cadherin and β -catenin
in the carcinogenesis of gastric cancer.
Materials and methods
Samples
Included in the study were 50 tumours and correspond-
ing normal samples, of which two tumours (17 and 23)
were from the same family, the rest sporadic (Table 1).
These cases were diagnosed by the Department of Pa-
thology, University Hospital of Iceland. Tissue was ob-
tained freshly on the day of surgery or from paraffin-
embedded material. Information concerning the tumour
stage, histotype and grade was also acquired from the
same department. DNA for PCR was isolated by the pro-
teinase K treatment [22]. RNA for RT-PCR was extracted
using Tri Reagent (Molecular Research Center, INC.
USA). For the A592T mutation, we screened 187 normal
individuals, 280 breast and 444 other cancer patients
with colon and rectum, lung, endometrium, ovary, testis,
kidney, thyroid carcinomas and sarcomas. All individual
identifiers were removed from the control samples prior
to analysis, and investigators were thus blinded to the
identification of samples which can no longer be traced
to specific individuals. Consent was presumed for the pa-
tient samples. For cases 294 and 728 with A592T muta-
tion, we analyzed their pedigrees and found that there
were no other cancer cases in the pedigree of case 294,
but there were other 5 cancer cases in the pedigree of
case 728, including 2 prostate cancers, 1 skin cancer, 1
lung cancer and 1 cancer of unclear origin.BMC Cancer 2001, 1:16 http://www.biomedcentral.com/1471-2407/1/16
Table 1: Summary of alterations of E-cadherin and β -catenin in a series of 50 gastric tumours.
Tumour Stage Type Grade LOH E-cad gene mutations Aberrant mRNA E-cad β -cat
Sample at 16q22.1 and polymorphisms of E-cad IHC IHC
1T 3 N 3 d i f f + I V S 1 + 6 T → C - +/- ++/-∇
3 T3N1 squ G1 + IVS4+10C→ GN D - + / -
17 T3N1 diff ND GTG(Val)→ GTC(Val) at cd832 ND - -
23 met + GCC(Ala)→ ACC(Thr) at cd592* ND +++/- +++/-
43 T3N2 diff + - - - +++/-
50 T3N1 diff - IVS1+6T→ C - ++/- ++/-
165 T3N1 int G3 ND - - +++/- +++/-∇
174 T3N2 int G3 - - ND +++/- ++/-
193 T3N2 int G3 + - ND -/+++ -/++
200 T3N1 int G2 - IVS4+10C→ G - ++/- +++/-
231 T3N0 mi G3 + - - ++/- ++/-∇
283 T3N0 int G3 ND - ND ++/- ++/-
287 T3N1 int G2 + - - -/+ ++/-
294 T3N1M1 mi G4 + GCC(Ala)→ ACC(Thr) at cd592♦ -+ + / - + + / - ∇
304 T3N3 int G2 - - - -/+++ +/-
308 T3N1 int G2 + - - +++/- ++/-
314 T3N1 diff - CAC(His)→ CAT(His) at cd632 - +++/- ++/-∇
GGC(Gly)→ GGT(Gly) at cd865
360 T2N1 int G3 + IVS4+10C→ G+ ♣ ++/- +/-
369 met + - +♣ +++/- ++/-
433 T3N1 mi G3 - IVS4+10C→ G - -/++ -/+
435 T2N0 int G3 + - - -/+++ -/++
443 T2N0 int G4 - - - +++/- +++/-
451 T4N0 int G2 ND - ND +++/- ++/-
474 T3N1 int G3 ND - ND - +/-
493 T3N1 int G3 + - - -/+++ +/-
503 T3N1 int G3 ND - - - +++/-
556 T3N2 int G2 - IVS1+6T→ CN D + + / - + / -
5'UTR-71C→ G
568 T3N2 mi G3 + - +♣ ++/- ++/-
612 T3N0 int G2 ND IVS4+10C→ G - +++/- +/-
AAC(Asn)→ AAT(Asn) at cd751
636 T3N1 diff + IVS4+10C→ G ND +++/- +++/-∇
650 T2N0M1 int G2 + - ND -/+ ++/-
675 T2N0 mi G3 + IVS4+10C→ G - +/- ++/-∇
676 T3N1 int G2 + - - +++/- -∇
680 T3N1 mi G3 + IVS1+6T→ C - ++/- ++/-
AAC(Asn)→ AAT(Asn) at cd751
694 T3N1 int G1 + - - +++/- +++/-
717 T3N1 int G3 + - +♣ -/+++ +++/-
726 T2N1 int G2 + IVS4+10C→ G - -/+++ ++/-
728 T3N0 int G2 + GCC(Ala)→ ACC(Thr) at cd592♦ - -/+++ ++/-
729 T3N1 int G1 - IVS1+6T→ C - -/+++ +++/-
732 T2N1 int G3 + - - -/+++ +++/-
735 T4N3 diff ND AAC(Asn)→ AAT(Asn) at cd751 - +++/- +++/-∇
738 T3N2 diff + - - - -∇
750 met ND AAC(Asn)→ AAT(Asn) at cd751 +♣ ++/- +++/-
755 T2N1 int G2 ND - +♥ +++/- ++/-
808 T3N0 int G1 + ACG(Thr)→ ACA(Thr) at cd251 +♠ +++/- ++/-
811 T2N1 int G2 + - - +++/- -/+
832 T3N2 int G2 + - - +++/- +++/-∇
855 T3N2 int G2 + - - +++/- +++/-
875 T3N2 int G2 - IVS4+10C→ G ND +++/- +++/-
904 T2N0 int G3 + IVS4+10C→ G - -/+++ ++/-
Useful 30 3 7 21 14
Total 40 50 38 50 50
% 75 6 18 42 28
T, tumour (size and invasiveness); N, node (degree of metastasis); M, metastasis; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; G4, not 
differentiated; diff, diffuse (degree of differentiation=G4); mi, mixed; int, intestine; met, metastatic tumour probably from stomach tumour; squ, squamous epithelial; LOH, 
loss of heterozygosity; E-cad, E-cadherin; β -cat, β -catenin; IHC, immunohistochemistry; cd, codon; UTR, untranslated region; +, positive LOH, aberrant E-cad mRNA, E-
cad and β -cat IHC;-, negative LOH, E-cadherin gene mutation, aberrant E-cad mRNA, E-cad and β -cat IHC; ND, not determined or not done; +/-, ++/- and +++/-, more 
than 50% cells positive; -/+, -/++ and -/+++, more than 50% cells negative; *, somatic mutation; ♦ , germline mutation; ♣ , insertion of intron 7 between exons 7 and 8, 
stop codon 374; ♥ , deletion of last 72 bases of exon 7, exon 8 and first 124 bases of exon 9, stop codon 322; ♠ , deletion of exons 8 and 9; deletion of last 84 bases of 
exon 8, stop codon 358; ∇ , these samples also showed cytoplasmic staining for β -catenin IHC.BMC Cancer 2001, 1:16 http://www.biomedcentral.com/1471-2407/1/16
LOH determination
Microsatellite markers used for LOH analysis of chromo-
some 16q were: D16S503, D16S496, D16S421, D16S545
and D16S512 for the region 16q22.1 containing E-cad-
herin locus (Genome Database). The polymerase chain
reaction (PCR) products were separated in an acryla-
mide sequencing gel and transferred to a positively-
charged nylon membrane, Hybond-N+ (Amersham,
Aylesbury, UK) and baked for at least 2 h at 80°C. The
non-radioactive detection method used to visualize the
PCR products has been described previously [23]. Auto-
radiograms were inspected visually by at least two re-
viewers, comparing the intensity of alleles from normal
and tumour DNA. The absence or a significant decrease
of one allele in the tumour compared to the normal ref-
erence sample was considered as LOH.
Mutation screening
All 16 exons of E-cadherin gene and exon 3 of β -catenin
gene were screened for inactivation mutations with a
PCR-SSCP (single strand conformation polymorphism)
analysis on genomic DNA templates. The primers for E-
cadherin and β -catenin used in the SSCP analysis were
described in our previous article [4] and Park et al.
[1999], respectively, and ordered from Pharmacia Bio-
tech or TAG Copenhagen A/S. Genomic DNA was used at
30 ng per 25 µl reaction mixture containing 5 pmol of the
forward and reverse primers, 2.5 nmol of each dNTP, 0.5
units of DynaZyme polymerase. The samples were am-
plified in 35 cycles composed of 30 s of denaturation at
94°C, 30 s of annealing at 55–70°C, and finally 60 s of ex-
tension at 72°C. A hot start was used by adding the en-
zyme in first cycle at around 70°C, after a preincubation
time of 5 min at 94°C. A 4 µl aliquot of PCR products was
mixed with 7 µl of formamide dye (95% formamide,
0.05% bromophenol blue and 0.05% xylene cyanol), de-
natured at 94°C for 10 min and snapcooled on ice. Aliq-
uots of 2 µl were analysed simultaneously on two non-
denaturing polyacrylamide gels (5% acrylamide with 2%
cross linking), either containing 5% glycerol or lacking
glycerol. Electrophoresis was performed in 1×  TBE on
vertical gels at 6w overnight or for 6 h at room tempera-
ture. The PCR products were visualized as the microsat-
ellite markers. Samples with abnormal mobility bands
were amplified again for 35 cycles as described above. A
5 µl aliquot of PCR products was then incubated with 10
U exonulease I and 2 U shrimp alkaline phosphatase to
remove excessive primers and dNTPs (US70995, Amer-
sham). Sequences of both strands were determined by
thermo sequenase DNA polymerase (Thermo Sequenase
Radiolabeled Terminator Cycle Sequencing Kit, Amer-
sham) using the two original PCR primers. We per-
formed the A592T mutation analysis on those cancers,
except the cancer of unclear origin, in the family of case
728 using direct sequencing.
Aberrant mRNA screening
1–5 µg of the total RNA was reversely transcribed into
cDNA using first strand cDNA synthesis kit (Amersham
Pharmacia Biotech). All samples were examined for E-
cadherin cDNA deletions and insertions. E-cadherin
cDNA was amplified using primer pairs Ex7-rEx10/2
and Ex9/2a-rEx11 for the region of exons 7–10 encoding
calcium binding sites [24]. PCR products were visualized
by agarose gel electrophoresis. Abnormal fragments
were excised and sequenced using forward and reverse
primers to determine the boundaries of the deletions and
insertions. Here, we used BigDye Terminator Cycle Se-
quencing Ready Reaction Kit (Perkin-Elmer, Foster City,
CA) and automated sequencer ABI PRISM™ 3100 (Per-
kin-Elmer) for sequencing
Immunohistochemical staining
Immunohistochemistry for E-cadherin and β -catenin
was performed on 5-µm sections from paraffin-embed-
ded tumour tissue blocks with monoclonal antibodies E-
cadherin 5H9 and Goat Anti-Catenin Beta (Research Di-
agnostic, Inc. NJ, USA), respectively, using the antigen
retrieval protocol described by Hazelbag et al. [1995].
Tumours were graded by intensity of staining as negative
(-), weakly positive (+), moderately positive (++) and
strongly positive (+++).
Statistical analysis
A Χ 2 test or Fisher's exact test was used to assess the re-
lationship between the above parameters.
Results
The frequency of LOH at 16q22.1 region was 75% (Table
1).
Three tumours (6%) showed the same missense muta-
tion A592T of exon 12, of which 2 cases had germline mu-
tation, and one case had somatic mutation. Information
for detected polymorphisms was included in Table 1.
Three of 187 (1.6%) normal individuals and 1 of 280
(0.36%) breast tumours showed this germline mutation.
The mutation was not found in 444 other tumours (Table
2).
Additionally, 3 of 280 breast tumours showed another
missense mutation GCC(Ala)→ TCC(Ser) at the identical
codon 592, of which 2 cases were germline mutation; the
third was unclear because the normal tissue was unavail-
able. The histological type of the 4 breast tumours was
ductal.
In the family of case 728, we found that the patient with
skin cancer and one of the patients with prostate cancer
showed the same germline mutation as case 728. Inter-
estingly, no mutations were detected in the tumour sam-BMC Cancer 2001, 1:16 http://www.biomedcentral.com/1471-2407/1/16
ples of these two cases. Probably, the mutated alleles
were lost during tumour development. The onset ages for
the cases with germline mutations in the pedigree were
78 years for case 728, 73 years for the skin cancer and 76
years for the prostate cancer.
We did not detect mutation by SSCP and DNA sequenc-
ing in exon 3 of the β -catenin gene in the 50 gastric tu-
mours.
Seven gastric tumours showed aberrant transcripts of
the E-cadherin. Tumours 360, 369, 568, 717 and 750 dis-
played insertion of intron 7 between exons 7 and 8. Tu-
mour 755 showed deletion of last 72 bases of exon 7, exon
8 and first 124 bases of exon 9. Tumour 808 displayed
two aberrant mRNAs, of which one had deletion of exons
8 and 9, and one case with deletion of last 84 bases of
exon 8 (Table 1).
Finally, we performed immunohistochemical staining of
E-cadherin and β -catenin. A regional variation of the
staining was detected across the tumours. The scorings
+/-, ++/- and +++/- refer to more than 50% cells posi-
tive, and scorings -/+, -/++ and -/+++ indicating more
than 50% cells negative. Negative (-) or reduced (-/+, -/
++, -/+++ and +/-) expression of E-cadherin and β -cat-
enin was detected in 21/50 (42%) and 14/50 (28%) cases,
respectively. Furthermore, for β -catenin IHC, 11 tu-
mours also showed positive cytoplasmic staining (Table
1). A significant association was found between negative
or reduced expression of E-cadherin and β -catenin (p =
0.048, Χ 2 test). Also we found an association between re-
duced expression of E-cadherin and diffuse histotype (p
= 0.04, Fisher's exact test).
Discussion
The high frequency of LOH at 16q22.1 region strongly
suggests that there are one or more tumour suppressor
genes in this region, whose loss could trigger carcinogen-
esis of gastric cancer. The E-cadherin gene has been
mapped to chromosome 16q22.1 [26]. The reduced ex-
pression and gene mutations of E-cadherin in several
types of cancers including gastric and lobular breast can-
cer have been identified, indicating that the E-cadherin
gene is a tumour suppressor gene [2–4], [13–17,27]. In
this study 3 cases (6%) showed the identical missense
mutation A592T. The calcium-binding motifs located in
the extracellular domains 1–5 are regarded as the key el-
ement for the function of E-cadherin, since a synthetic
molecule with a single amino-acid substitution in a calci-
um-binding motif showed no adhesiveness [28]. Also, in
human cell line MKN45 from gastric cancer, which
lacked tight cell-cell adhesion, a 4-amino-acid deletion
was found at the boundary between exons 6 and 7, which
was considered to alter the conformation surrounding
the key calcium-binding motifs and to abolish the adhe-
sive property of the E-cadherin molecules [29]. The sin-
gle amino-acid substitution in the present study is
located within the fifth extracellular domain of E-cad-
herin, where a calcium-binding motif could exist. It is
conceivable, therefore, that the mutations in the three
cases also destroyed function of the E-cadherin. Interest-
ingly, the three cases also showed LOH at 16q22.1 con-
taining the E-cadherin locus. So it can be considered that
two genetic events resulting in inactivation of the gene
occurred in the two alleles of E-cadherin gene, respec-
tively. The findings above indicated that the E-cadherin
gene is a tumour-suppressor gene because it is in accord-
ance with the classical two-hit theory for tumour sup-
pressor genes [30]. Previous studies in lobular breast
cancer also support this opinion [4,14]. In cell line
MKN45 mentioned above (poorly differentiated adeno-
carcinoma) with weak cell-cell adhesion, a 12-bp in
frame deletion of E-cadherin gene and loss of the wild
type allele were detected [29]. But this cell line still
showed strong expression of mRNAs and proteins, sug-
gesting that not only reduced expression but also struc-
tural abnormalities themselves may result in
inactivation of the E-cadherin-mediated cell adhesion
system [29]. Therefore, a single amino-acid substitution
found in this study may cause structural changes of E-
cadherin and result in limited cell-cell adhesion, al-
though two of the cases (23 and 294) showed sufficient
protein expression.
Interestingly, the same sequence variant of somatic and
germline mutation was found simultaneously in differ-
ent gastric patients. Case 23 with somatic mutation had
an onset age of 56 years, but cases 294 and 728 with
germline mutation had onset ages of 71 and 78 years, re-
spectively. One explanation for this phenomenon could
be that loss of second allele of E-cadherin in case 23 oc-
curred very early, thereby triggerring carcinogenesis rel-
atively early in case 23. But there is another possibility
that this mutation in case 23 played a role only in pro-
Table 2: Frequency of A592T missense mutation in gastric can-
cer, other cancer and normal individuals
Variables A592T/total %
Gastric cancer 3/50 6
Breast cancer 1/280 0.36
Other cancer* 0/444 0
Normal population 3/187 1.6
* including colon and rectum, lung, endometrium, ovary, testis, kidney, 
thyroid carcinomas and sarcomas.BMC Cancer 2001, 1:16 http://www.biomedcentral.com/1471-2407/1/16
gression of the tumour, but not in the initiation, where
other genetic events could probably be responsible for
the initiation of the gastric cancer. But cases 294 and 728
with germline mutations had late onset age. This may be
because the inactivation of another allele occurred very
late. An article reported that the obligatory carriers with
truncated mutations in E-cadherin gene in their 80s and
90s remained unaffected [31]. Therefore, further identi-
fication of genetic and/or environmental modifiers that
might account for the variable age of onset should be car-
ried out. Specially, case 294 had three tumours in the
stomach, which is in line with genetic tumours usually
being multiple [30].
The frequency (6%) of mutation A592T in 50 gastric tu-
mours is almost four-fold that in normal population,
suggesting again that this mutation indeed contributed
to the tumourigenesis in a subset of gastric tumours.
Futhermore, 0.36% of breast tumours, and no other tu-
mours, showed identical germline mutation, indicating
that there could be a histological difference for this mu-
tation in gastric cancer and other cancer.
Only other two cases exhibited A592T mutation in the
family of case 728. Specially, this mutation was detected
only in corresponding normal tissue, but not in the tu-
mour tissue, suggesting that the mutated alleles were lost
during the tumourigenesis. From these we can conclude
that this mutation may not play a role in the tumourigen-
esis of prostate and skin cancer, but it could be gastric-
cancer specific.
We conclude that the A592T mutation may increase the
lifetime risk of developing gastric cancer, but is clearly a
sequence variant of low penetrance. Our findings of two
different sequence variants at codon 592 (A592T and
A592S), as germline and somatic mutations, suggest that
this codon is a hotspot of mutations in tumour pathogen-
esis.
The breakpoints for insertions of intron 7 and deletion of
exons 8 and 9 are at splicing sites, in accordance with
"GU-AG" rule for mRNA splicing. It may be speculated
that these alterations were not generated by alternative
splicing, since no evidences for alternative splicing were
found within mouse E-cadherin gene [32] and no aber-
rant mRNAs were detected in noncancerous tissues. The
mutations at splicing sites ought to be responsible for the
alterations of E-cadherin mRNAs, although no muta-
tions were found on DNA level in this study, presumably
because the SSCP used for mutation screening has a low
efficiency. An additional 2 deletions showed breakpoints
at non-splicing sites, whose splicing is not in line with
"GU-AG" rule, possibly indicating that a rearrangement
in genomic level may cause the aberrant mRNAs. Previ-
ous studies have shown skipping of exon 8 or 9 in gastric
cancer [24,33]. These aberrations may result in E-cad-
herins losing calcium-binding motifs due to lack of exons
8 and 9, and truncated molecules because of frameshift
mutations caused by insertions and deletions, finally fa-
cilitating scattering of carcinoma cells.
Reduced expression of E-cadherin and β -catenin has
been found in some cancers including gastric cancer [8].
Heterogeneous or unstable expression for both E-cad-
herin and β -catenin across the tumours was found. It has
been demonstrated that in 40% of adenocarcinomas E-
cadherin levels were raised in their intravascular tumour
components in comparison to their extravascular com-
partments [34]. One explanation may be that entrance of
a carcinoma into an intravascular compartment is asso-
ciated with an upregulation of E-cadherin expression,
and that subsequent exit into extravascular tissues is as-
sociated with downregulation [35]. Since E-cadherin and
β -catenin are the crucial components to form cell-cell ad-
hesion complex, loss of them may result in the disruption
of the function of the complex, which may cause weak
cell-cell adhesion and confer invasive properties on a tu-
mour. Furthermore, reduced cell-cell adhesion is associ-
ated with loss of contact inhibition of proliferation,
thereby allowing escape from growth control signal, fi-
nally triggering carcinogenesis of human cancer [8]. In
this study, an association between abnormal expression
of E-cadherin and β -catenin was found, suggesting that
loss of E-cadherin binding may cause a redistribution of
β -catenin from the cell membrane to the cytoplasm. The
increased free β -catenin in the cytoplasm could translo-
cate to the nucleus and lead to activation of gene expres-
sion. This is supported by the findings that two cases
(676 and 738) showed negative staining in the inner sur-
face of membrane and positive staining in cytoplasm, si-
multaneously. But other 9 tumours (table 1) showing
moderate or strong staining in membrane also exhibited
positive staining in cytoplasm, suggesting that the nor-
mal degradation of the free β -catenin in cytoplasm is in-
hibited. Also, we found an association between abnormal
expression of E-cadherin and diffuse histotype, indicat-
ing that the alterations of the E-cadherin may play a role
in poorly-differentiated gastric tumours. Interestingly,
aberrant expression of E-cadherin and/or the catenins
has been shown to be an independent prognostic marker
for short survival in gastric cancer patients [8]. Of partic-
ular interest is the finding that E-cadherin is an inde-
pendent predictor of occult lymph node and
micrometastasis in nodes classified as No by routine his-
topathological methods [8].
Conclusions
Our results support that alterations of E-cadherin and β -
catenin play a role in the initiation and progression ofBMC Cancer 2001, 1:16 http://www.biomedcentral.com/1471-2407/1/16
gastric cancer. Expression of both genes are reduced in
gastric cancer, but the mechanism of downregulation is
not clear. LOH, mutations and alterations in RNA splic-
ing could explain a part of the downregulation of the E-
cadherin in gastric cancer.
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